Literature DB >> 31401730

Could quantitative real-time polymerase chain reaction assay serve as an alternative test method to evaluate human epidermal growth factor receptor 2 status of gastric carcinoma in the South Asian setting?

D K S Kannangara1, M D S Lokuhetty2, D Subasinghe3, Y I N S Gunawardene4, R S Dassanayake5.   

Abstract

BACKGROUND: Human epidermal growth factor receptor 2 (HER2) protein overexpression and/or HER2 gene amplification are/is linked to a dismal outcome of gastric carcinoma (GCa). Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) are key methods to identify patients for HER2 targeted therapy. Drawbacks of both the methods warrant novel tests. Hence, we evaluated the value of quantitative real-time polymerase chain reaction (qPCR) as an alternative test method, relative to IHC to detect HER2 status of GCa and to find relationship between these  results with demographic/clinicopathological data.
METHOD: Twenty GCa patients with known IHC HER2 scores were evaluated. qPCR was performed for the HER2 gene and amyloid precursor protein (reference gene) in formalin-fixed paraffin-embedded GCa tissue. Cycle threshold values (Ct) were analyzed using the Pfaffl method to detect HER2 gene amplification.
RESULTS: HER2 positivity rates by IHC and qPCR were 20% and 35%, respectively. The sensitivity and specificity of qPCR were 67% and 76%, respectively, relative to IHC. qPCR results were reproducible. The diagnostic consistency between IHC and qPCR (κ = 0.146) was slightly agreeable (0.01 < k < 0.20), with a 65% concordance. Based on McNemar's test, there was no significant difference between the results of the two tests. IHC HER2 protein expression had relationship with the tumor (TNM) stage and Lauren histological type (p < 0.05). Positive HER2 gene expression by qPCR showed relationship with depth of invasion, lymph node involvement, and degree of differentiation (p < 0.05).
CONCLUSION: Cost-effective qPCR could serve as an alternative test method for detection of HER2 status of GCa. Both HER2 overexpression by IHC and gene amplification by qPCR are associated with adverse clinicopathological features.

Entities:  

Keywords:  Gastric carcinoma; HER2 status; Quantitative PCR assay

Mesh:

Substances:

Year:  2019        PMID: 31401730     DOI: 10.1007/s12664-019-00955-6

Source DB:  PubMed          Journal:  Indian J Gastroenterol        ISSN: 0254-8860


  19 in total

1.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Authors:  Yung-Jue Bang; Eric Van Cutsem; Andrea Feyereislova; Hyun C Chung; Lin Shen; Akira Sawaki; Florian Lordick; Atsushi Ohtsu; Yasushi Omuro; Taroh Satoh; Giuseppe Aprile; Evgeny Kulikov; Julie Hill; Michaela Lehle; Josef Rüschoff; Yoon-Koo Kang
Journal:  Lancet       Date:  2010-08-19       Impact factor: 79.321

2.  c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems.

Authors:  H Allgayer; R Babic; K U Gruetzner; A Tarabichi; F W Schildberg; M M Heiss
Journal:  J Clin Oncol       Date:  2000-06       Impact factor: 44.544

3.  [Her2 testing in gastric cancer. What is different in comparison to breast cancer?].

Authors:  J Rüschoff; I Nagelmeier; G Baretton; M Dietel; H Höfler; H U Schildhaus; R Büttner; W Schlake; O Stoss; H H Kreipe
Journal:  Pathologe       Date:  2010-05       Impact factor: 1.011

4.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Authors:  D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

5.  Comparison of immunohistochemistry, four in situ hybridization methods and quantitative polymerase chain reaction for the molecular diagnosis of HER2 status in gastric cancer: a study of 55 cases.

Authors:  Libor Staněk; Tomáš Rozkoš; Jan Laco; Aleš Ryška; Luboš Petruželka; Miroslav Důra; Pavel Dundr
Journal:  Mol Med Rep       Date:  2014-09-02       Impact factor: 2.952

6.  Effect of HER-2/neu over-expression on prognosis in gastric cancer: a meta-analysis.

Authors:  Shuyi Wang; Gang Zheng; Liangdong Chen; Bin Xiong
Journal:  Asian Pac J Cancer Prev       Date:  2011

7.  Real-time PCR complements immunohistochemistry in the determination of HER-2/neu status in breast cancer.

Authors:  Andreea Nistor; Peter H Watson; Norman Pettigrew; Karim Tabiti; Angelika Dawson; Yvonne Myal
Journal:  BMC Clin Pathol       Date:  2006-01-18

8.  Expression and sub-cellular localization of an epigenetic regulator, co-activator arginine methyltransferase 1 (CARM1), is associated with specific breast cancer subtypes and ethnicity.

Authors:  Melissa B Davis; Xinyu Liu; Shiyao Wang; Jaxk Reeves; Andrey Khramtsov; Dezheng Huo; Olufunmilayo I Olopade
Journal:  Mol Cancer       Date:  2013-05-10       Impact factor: 27.401

9.  Assessing HER2 amplification by IHC, FISH, and real-time polymerase chain reaction analysis (real-time PCR) following LCM in formalin-fixed paraffin embedded tissue from 40 women with ovarian cancer.

Authors:  Thore Hillig; Jørgen Thode; Marie F Breinholt; Maria-Benedicte Franzmann; Carsten Pedersen; Flemming Lund; Henrik Mygind; György Sölétormos; Martin Rudnicki
Journal:  APMIS       Date:  2012-06-26       Impact factor: 3.205

10.  Detection of Her-2/neu expression in gastric cancer: Quantitative PCR versus immunohistochemistry.

Authors:  Guang-Jun Zhu; Chun-Wei Xu; Mei-Yu Fang; Yu-Ping Zhang; Yang Li
Journal:  Exp Ther Med       Date:  2014-09-22       Impact factor: 2.447

View more
  1 in total

1.  Evaluating the presence of Mycoplasma hyorhinis, Fusobacterium nucleatum, and Helicobacter pylori in biopsies of patients with gastric cancer.

Authors:  Camila do Nascimento Araujo; Aline Teixeira Amorim; Maysa Santos Barbosa; Julieta Canjimba Porto Lucas Alexandre; Guilherme Barreto Campos; Cláudia Leal Macedo; Lucas Miranda Marques; Jorge Timenetsky
Journal:  Infect Agent Cancer       Date:  2021-12-23       Impact factor: 2.965

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.